Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Allergy Immunotherapy Market Will Surpass US$ 3.33 Billion by 2025 End - Future Market Insights

This image opens in the lightbox

News provided by

Future Market Insights

15 Mar, 2019, 12:00 GMT

Share this article

Share toX

Share this article

Share toX

VALLEY COTTAGE, New York, March 15, 2019 /PRNewswire/ -- Increasing incidences of allergies and inefficient treatment methodologies, such as pharmacotherapy, for controlling the occurrence rate of allergies are fuelling adoption of allergy immunotherapy, which is deemed as a designated cure for various types of allergies. A notable shift of patients and healthcare providers towards allergy immunotherapy has been observed, owing to its competency to change the course of the disease and improve the immunological resistance.

Development of new products to cure allergies is expected to reflect positively on the growth of the global allergy immunotherapy market. Analysing a cohort of these factors, a new report published by Future Market Insights opines that the allergy immunotherapy market is poised to surpass a valuation of US$ 3.33 billion with an impressive CAGR of over 10% through 2025.

According to the study, growing focus on taking preventive measures against chronic illnesses is also catalysing the allergy immunotherapy market. The American College of Allergy, Asthma and Immunology anticipates that allergies are the sixth-most significant reason for the occurrence of the chronic illness in the North America region. As stated by the Centers for Disease Control and Prevention (CDC), over 50 Mn Americans suffer from various types of allergies every year. Moreover, it is estimated that by the end of 2025, about 50% of the population will suffer from allergic diseases.

Request a Sample Report with Table of Contents and Figures: https://www.futuremarketinsights.com/reports/sample/rep-gb-9043

Novel Product Launches in Sublingual Immunotherapy Segment to Offer Lucrative Growth Opportunities to the Allergy Immunotherapy Market

Depending on the treatment type, the sublingual immunotherapy drugs segment is expected to hold a prominent share in the allergy immunotherapy market during the forecast period. This is attributed to the United States

Food and Drug Administration (FDA) approval for sublingual therapy. Launch of novel therapies such as Ragwitek, Grastek, and Oralair has significantly influenced the allergy immunotherapy market growth. In addition to this, development of Odactra to treat the allergy caused by house dust mite is projected to trigger the growth of allergy immunotherapy market.

Hospital Pharmacy Remains the Preferred Distribution Channel in Allergy Immunotherapy Market

According to the FMI study, hospital pharmacy remains a preferred distribution channel, and the status quo is likely to continue throughout the forecast period. The study opines this segment to grow at a significant CAGR through 2025, on the back of wide availability of allergy immunotherapy products and drugs at the hospital pharmacies. Sales are also surging through online channels, with this segment likely to account for over 12% CAGR by the end of 2025, owing to the development of leading pharmaceutical chains.

Preview Allergy immunotherapy market is segmented by (Distribution channel - online pharmacies, retail pharmacies and drug stores & hospital pharmacies; Treatment type - sublingual immunotherapy & subcutaneous immunotherapy; Allergy type - asthma, allergic rhinitis, venom allergy & food allergy among others;) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2025: https://www.futuremarketinsights.com/reports/allergy-immunotherapy-market

Popularity of Allergy Immunotherapy in Europe to Lend Lucrative Growth Opportunity Market Players

According to the report, Europe is projected to account for the largest share of the allergy immunotherapy market during the forecast period. The growing size of the allergy immunotherapy market in this region can be attributed to the pervasiveness of allergic disorders, development of novel therapies, and high budget sanctioned for the R&D of an effective cure. As a result, Europe procures a prominent share with a notable CAGR of 11.5% in the global allergy immunotherapy market.

Growing awareness of the allergy and its treatment in parallel to the development of the effective products have considerably influenced the growth of the allergy immunotherapy market in North America. Asia Pacific is envisaged to witness a steady growth of the allergy immunotherapy market throughout the forecasted period.

Buy this report @ https://www.futuremarketinsights.com/checkout/9043

Novel Products Launched by Manufacturers to Bolster Growth of the Allergy Immunotherapy Market

Some of the key players of the global allergy immunotherapy market comprise WOLW Pharma, Holister Stier, Leti, Allergopharma, Stallergenes, Greer, Allergy Therapeutics, ALK-Abello A/S, HAL Allergy Group, Biomay AG, Circassia, DBV Technologies, Aimmune Therapeutics, and Merck KGaA, among others. Below are the insights into the key developments of these players.

  • In the year 2014, United States FDA approved the product of Stallergeners S.A., ORALAIN, as it became the first immunotherapy tablet for curing allergic rhinitis caused by grass pollen.
  • In 2014 itself, Alk-Albeno A/S received approval for the launch of Grastek as an effective cure for treating allergic rhinitis.

Such neoteric development and product launches are expected to boost the global allergy immunotherapy market. 

Our advisory services are aimed at helping you with specific, customized insights that are relevant to your specific challenges. Let us know about your challenges and our trusted advisors will connect with you: https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-9043

More from Healthcare, Pharmaceuticals and Medical devices Market Insights Market Intelligence:

  • Metagenomics Analysis: Past and Future Trends - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018-2028
  • Surgical Pliers Market Analysis - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018-2028
  • Handheld Arthroscopic Instruments Market Analysis - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018-2028

About Us

Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights and an aerial view of the competitive framework and future market trends.

Browse More Healthcare, Pharmaceuticals and Medical devices Market Insights

Contact Us

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
T (UK): +44(0) 20-7692-8790

Sales: sales@futuremarketinsights.com 
Press Office: Press@futuremarketinsights.com 
Blog: Market Research Blog 
Website: https:www.futuremarketinsights.com

Modal title

Also from this source

Isoprene Rubber Latex Market is Projected to Expand at a CAGR of 8.1% between 2024 and 2034 | Future Market Insights, Inc.

Isoprene Rubber Latex Market is Projected to Expand at a CAGR of 8.1% between 2024 and 2034 | Future Market Insights, Inc.

The isoprene rubber latex industry is predicted to be valued at USD 922 million by 2024. The market valuation is estimated to be USD 2,005.3 million...

Growing Demand for Premium Distilled Agave-based Beverages to Propel Mezcal Market at a CAGR of 14.2% by 2034 | Future Market Insights, Inc.

Growing Demand for Premium Distilled Agave-based Beverages to Propel Mezcal Market at a CAGR of 14.2% by 2034 | Future Market Insights, Inc.

According to Future Market Insights (FMI), the global mezcal market demand is estimated to reach a valuation of USD 635 million by 2024. Over the...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Pharmaceuticals

Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.